Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Merck & Co., Inc. Statement On Medicare Part D Assistance
Merck & Co., Inc. said it supports a proposal to provide additional assistance to Medicare Part D beneficiaries who have reached the coverage gap (donut hole) in their prescription benefit.
generic viagra online
Growth In German Children
German children are taller than 30 years ago, but the increase in height observed during the last century has become slower. In the current edition of Deutsches Arzteblatt International (Dtsch Arztebl Int 2009; 106(23): 377-82), Bettina Gohlke and Joachim Woelfle of the Department of Pediatrics at the University of Bonn summarize the current state of knowledge of changes in height and of the physical development of young people.
News of the day
Children Now Enjoy More Freedom At Home, But Are More Restricted Outside The Home
Children have certainly mastered the art of selecting, negotiating and even refusing the chores their parents assign to them. This growth in personal autonomy at home over the last few decades could be the result of shrinking opportunities to participate in activities outside the home, without Mom and Dad looking over their shoulder, according to Dr. Markella Rutherford from Wellesley College in the US. Her analysis1 of back issues of the popular US magazine, Parents, maps how the portrayal of parental authority and children"s autonomy has changed over the last century. Her findings are published online in Springer"s journal Qualitative Sociology.
Diagnostics

2009/044 NICE Issues Final Guidance On The Use Of Rituximab For First Line Chronic Lymphocytic Leukaemia

The National Institute for Health and Clinical Excellence (NICE) has today (22 July) published guidance on the use of rituximab for the first line treatment of chronic lymphocytic leukaemia. The guidance recommends that rituximab should be considered asa possible first treatment for people with chronic lymphocytic leukaemia who are able to take fludarabine in combination with cyclophosphamide. Rituximab should only be used in combination with fludarabine and cyclophosphamide. Rituximab is not recommended in combination with any other chemotherapy agents as a first treatment for chronic lymphocytic leukaemia. Chronic lymphocytic leukaemia is the most common form of adult leukaemia and is a cancer of the white blood cells (lymphocytes). The cancerous lymphocytes multiply in an uncontrolled way and stop normal white blood cells, red blood cells and platelets (blood fragments that have a role in the clotting of blood) from working properly. Dr Carole Longson, NICE Health Technology Evaluation Centre Director said: "After looking at all of the available evidence the independent Appraisal Committee concluded that rituximab, when used as a first line treatment for people with with chronic lymphocytic leukaemia who are able to take fludarabine in combination with cyclophosphamide, represented an effective use of NHS res. This important guidance increases the treatment options available to people with this condition, wherever they live in England and Wales." NICE


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009